Filing Flows › Alnylam Pharmaceuticals (ALNY) › Free cash flow
Alnylam Pharmaceuticals (ALNY) free cash flow by quarter
Alnylam Pharmaceuticals' free cash flow was $271M in Q3 2026 (third quarter 2026), +93% from Q4 2025. Over the last 4 quarters it ranged from $139M (Q2 2025) to $313M (Q3 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $271M | +93% | -13% |
| Q4 2025 | $140M | -55% | — |
| Q3 2025 | $313M | +124% | — |
| Q2 2025 | $139M | — | — |
Q3 2026 at a glance
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.
Questions
What is Alnylam Pharmaceuticals' free cash flow?
Alnylam Pharmaceuticals' free cash flow was $271M in Q3 2026 (third quarter 2026), +93% from Q4 2025.
How has Alnylam Pharmaceuticals' free cash flow changed?
Over the last 4 quarters it ranged from $139M (Q2 2025) to $313M (Q3 2025).
Q3 2026 results → · How Alnylam Pharmaceuticals makes money →